90 related articles for article (PubMed ID: 29054374)
21. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
22. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
McMullen KP; deGuzman AF; McCullough DL; Lee WR
Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
[TBL] [Abstract][Full Text] [Related]
23. The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy.
Herbert C; Morris WJ; Hamm J; Lapointe V; McKenzie M; Pickles T; Spadinger I; Keyes M
Brachytherapy; 2011; 10(6):442-8. PubMed ID: 21398190
[TBL] [Abstract][Full Text] [Related]
24. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
Nobes JP; Khaksar SJ; Hawkins MA; Cunningham MJ; Langley SE; Laing RW
Radiother Oncol; 2008 Jul; 88(1):121-6. PubMed ID: 18499289
[TBL] [Abstract][Full Text] [Related]
25. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
26. Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: outcome and toxicity.
Yamada Y; Masui K; Iwata T; Naitoh Y; Yamada K; Miki T; Okihara K
Brachytherapy; 2015; 14(2):118-23. PubMed ID: 25304650
[TBL] [Abstract][Full Text] [Related]
27. Ten-year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience.
Wilson C; Waterhouse D; Lane SE; Haworth A; Stanley J; Shannon T; Joseph D
J Med Imaging Radiat Oncol; 2016 Aug; 60(4):531-8. PubMed ID: 27020620
[TBL] [Abstract][Full Text] [Related]
28. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
[TBL] [Abstract][Full Text] [Related]
29. Adaptive cone-beam CT planning improves long-term biochemical disease-free survival for
Peters M; Smit Duijzentkunst DA; Westendorp H; van de Pol SMG; Kattevilder R; Schellekens A; van der Voort van Zyp JRN; Moerland MA; van Vulpen M; Hoekstra CJ
Brachytherapy; 2017; 16(2):282-290. PubMed ID: 28110899
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
31. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
32. 125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy.
Keyes M; Pickles T; Agranovich A; Kwan W; Morris WJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):40-50. PubMed ID: 15337538
[TBL] [Abstract][Full Text] [Related]
33. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
Khaksar SJ; Laing RW; Henderson A; Sooriakumaran P; Lovell D; Langley SE
BJU Int; 2006 Dec; 98(6):1210-5. PubMed ID: 17034501
[TBL] [Abstract][Full Text] [Related]
34. Which patients benefit from post-implant CT dosimetry after real-time intraoperative planning for low dose rate prostate brachytherapy? Case series and systematic literature review.
Mitina N; Christie D; Hill B; Middlebrook N; Nadezhdin N
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):260-7. PubMed ID: 26568444
[TBL] [Abstract][Full Text] [Related]
35. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
36. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
38. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003.
Cosset JM; Flam T; Belin L; Thiounn N; Pierrat N; Pontvert D; Wakil G; Savignoni A; Chauveinc L
Cancer Radiother; 2016 Jun; 20(4):261-7. PubMed ID: 27318554
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study.
Nguyen PL; Chen MH; D'Amico AV; Tempany CM; Steele GS; Albert M; Cormack RA; Carr-Locke DL; Bleday R; Suh WW
Cancer; 2007 Oct; 110(7):1485-92. PubMed ID: 17701957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
